Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or non-pregnant, non-breast feeding female;~2. Aged between 18 and 75 years;~3. Stage IIIB, stage IIIC or stage IV melanoma with:~   * At least 2 cutaneous or subcutaneous non necrotic accessible tumours;~  * Tumour size of 1 to 1.5 cm diameter;~  * No minimum distance between the 2 selected lesions;~4. Progressive melanoma not responding to previous treatments or patients refusing other therapies;~5. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;~6. For women of child-bearing age: effective contraception method (oral contraception or intra-uterine device) used for more than 2 months before the 1st administration and to be maintained for 3 months after the last administration of Plasmid AMEP;~7. Having given a written informed consent.~Exclusion Criteria:~1. Patients who can benefit from other melanoma treatments including surgery;~2. Significant cardiac arrhythmias, electronic pacemakers, defibrillators, or any implanted electronic device;~3. Recent (less than 6 months) acute vascular diseases (stroke, MI...);~4. Advanced peripheral arterial diseases, venous ulcers, or scleroderma;~5. History or treatment of seizures within the last 5 years;~6. Clinically significant abnormality at pre-study full physical examination;~7. Any clinically significant ECG abnormalities;~8. Prior systemic therapy or any other antineoplastic treatments within the last 4 weeks, radiotherapy or surgery unrelated to the fields in question are allowed;~9. Abnormal renal function (creatinine plasma level \> ULN);~10. Abnormal liver function tests (any of the following):~    * PT \< 70%, ASAT, ALAT, alkaline phosphatases, GGT and/or total bilirubin \> ULN in the absence of liver metastasis;~   * PT \< 70%, ASAT, ALAT \> 2 ULN, alkaline phosphatases \> 1.5 ULN, GGT \> 5 ULN and/or total bilirubin \> 3 ULN in the case of liver metastases;~11. Abnormal bone marrow function: haemoglobin \< 10g/dL, WBC \< 3.109 /L and/or platelet count \< 100.103 /L;~12. Clinically significant abnormality in pre-study laboratory tests;~13. Evidence of significant active infection (e.g., pneumonia, wound abscess, etc);~14. Intractable coagulopathy;~15. Any significant disease, including psychiatric and dermatology diseases that may affect the proper evaluation of efficacy or safety;~16. Patients who had participated in another clinical trial in the last 30 days prior to enrolment in the present clinical trial;~17. Patients unwilling or unable to comply with protocol requirements and scheduled visits.~Note: patients with brain metastases, or waiting for other therapies (i.e. isolated limb perfusion) may be included.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Plasmid AMEP electrotransfer (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).